Recombinant Protein & VLP Vaccines

Recombinant Protein & VLP Vaccines includes companies developing vaccines built from recombinant antigens or virus-like particles. These approaches often aim to improve immunogenicity, safety, or manufacturability compared with older vaccine formats.

Why watch Recombinant Protein & VLP Vaccines

This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.

Latest Recombinant Protein & VLP Vaccines news

The latest feed items from companies currently grouped under Recombinant Protein & VLP Vaccines.

1. 01
   2021-03-08 23:00 EST

   NVAXNovavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

   Source: Novavax

2. 02
   2021-03-01 21:02 EST

   NVAXNovavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

   Source: Novavax

3. 03
   2021-03-01 12:11 EST

   NVAXノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始

   Source: Novavax

4. 04
   2021-02-26 13:23 EST

   NVAXNovavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

   Source: Novavax

5. 05
   2021-02-22 12:00 EST

   NVAXNovavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico

   Source: Novavax

6. 06
   2021-02-18 21:02 EST

   NVAXNovavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

   Source: Novavax

7. 07
   2021-02-16 13:00 EST

   NVAXNovavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021

   Source: Novavax

8. 08
   2021-02-16 01:04 EST

   NVAXNovavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea

   Source: Novavax

9. 09
   2021-02-04 22:05 EST

   NVAXNovavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt

   Source: Novavax

10. 10
    2021-02-04 21:05 EST

    NVAXNovavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization

    Source: Novavax

11. 11
    2021-02-04 02:14 EST

    NVAXNovavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine

    Source: Novavax

12. 12
    2021-02-02 17:31 EST

    NVAXNovavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada

    Source: Novavax

13. 13
    2021-02-02 00:32 EST

    NVAXNovavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science

    Source: Novavax

14. 14
    2021-01-28 21:05 EST

    NVAXNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

    Source: Novavax

15. 15
    2021-01-22 22:23 EST

    NVAXNovavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

    Source: Novavax

16. 16
    2021-01-22 21:49 EST

    NVAXNovavax Names Madelyn Caltabiano Senior Vice President, Global Program Management

    Source: Novavax

17. 17
    2021-01-15 13:00 EST

    NVAXRegulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer

    Source: Novavax

18. 18
    2021-01-07 23:14 EST

    NVAXNovavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

    Source: Novavax

19. 19
    2021-01-06 14:00 EST

    NVAXNovavax to Participate in Upcoming Conferences

    Source: Novavax

20. 20
    2020-12-28 14:21 EST

    NVAXNovavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

    Source: Novavax

Companies in Recombinant Protein & VLP Vaccines

2 companies tagged with Recombinant Protein & VLP Vaccines.

Frequently Asked Questions